Compare Stocks: XBIT, BCYC, GALT, and MGNX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$3.38 -5.1%	$3.96	$3.33 ▼ $9.16	$236.58M	1.68	437,341 shs	728,668 shs
GALT Galectin Therapeutics	$3.90 +3.7%	$3.74	$2.03 ▼ $7.13	$256.84M	0.38	294,776 shs	220,095 shs
MGNX MacroGenics	$3.58 -0.6%	$4.01	$1.29 ▼ $5.08	$228.05M	1.2	540,544 shs	980,529 shs
XBIT XBiotech	$2.19 -0.5%	$2.24	$2.09 ▼ $3.44	$66.77M	0.79	33,518 shs	25,235 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	-8.15%	-20.28%	-22.30%	-59.42%
GALT Galectin Therapeutics	0.00%	0.00%	-10.34%	-13.53%	-6.70%
MGNX MacroGenics	0.00%	-4.28%	-15.76%	-23.99%	+110.59%
XBIT XBiotech	0.00%	+0.92%	-0.45%	-4.78%	-17.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$3.38 -5.1%	$3.96	$3.33 ▼ $9.16	$236.58M	1.68	437,341 shs	728,668 shs
GALT Galectin Therapeutics	$3.90 +3.7%	$3.74	$2.03 ▼ $7.13	$256.84M	0.38	294,776 shs	220,095 shs
MGNX MacroGenics	$3.58 -0.6%	$4.01	$1.29 ▼ $5.08	$228.05M	1.2	540,544 shs	980,529 shs
XBIT XBiotech	$2.19 -0.5%	$2.24	$2.09 ▼ $3.44	$66.77M	0.79	33,518 shs	25,235 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	-8.15%	-20.28%	-22.30%	-59.42%
GALT Galectin Therapeutics	0.00%	0.00%	-10.34%	-13.53%	-6.70%
MGNX MacroGenics	0.00%	-4.28%	-15.76%	-23.99%	+110.59%
XBIT XBiotech	0.00%	+0.92%	-0.45%	-4.78%	-17.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.44	Hold	$13.86	309.97% Upside
GALT Galectin Therapeutics	2.00	Hold	$11.00	182.05% Upside
MGNX MacroGenics	2.17	Hold	$6.33	76.91% Upside
XBIT XBiotech	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XBIT, BCYC, GALT, and MGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/14/2026	GALT Galectin Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/14/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	MGNX MacroGenics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.00 ➝ $11.00
8/11/2026	GALT Galectin Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/5/2026	MGNX MacroGenics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/30/2026	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $14.00
7/13/2026	GALT Galectin Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/8/2026	BCYC Bicycle Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$72.86M	3.25	N/A	N/A	$8.79 per share	0.38
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.99) per share	N/A
MGNX MacroGenics	$149.50M	1.53	N/A	N/A	$0.88 per share	4.07
XBIT XBiotech	N/A	N/A	N/A	N/A	$4.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$218.96M	-$2.73	N/A	N/A	N/A	-311.11%	-33.22%	-27.79%	10/29/2026 (Estimated)
GALT Galectin Therapeutics	-$30.84M	-$0.43	N/A	N/A	N/A	N/A	N/A	-176.83%	11/13/2026 (Estimated)
MGNX MacroGenics	-$74.62M	-$0.22	N/A	N/A	N/A	-8.70%	-109.26%	-18.70%	11/11/2026 (Estimated)
XBIT XBiotech	-$45.54M	-$1.48	N/A	N/A	N/A	N/A	-31.62%	-30.29%	N/A

Latest XBIT, BCYC, GALT, and MGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	BCYC Bicycle Therapeutics	-$0.3990	N/A	N/A	N/A	$12.22 million	N/A
8/14/2026	Q2 2026	GALT Galectin Therapeutics	-$0.09	-$0.14	-$0.05	-$0.14	N/A	N/A
8/13/2026	Q2 2026	MGNX MacroGenics	-$0.0779	$0.31	+$0.3879	$0.31	$59.14 million	$32.83 million
8/13/2026	Q2 2026	XBIT XBiotech	$0.03	-$0.22	-$0.25	-$0.22	$7.00 million	N/A
7/30/2026	Q2 2026	BCYC Bicycle Therapeutics	-$0.5756	-$0.72	-$0.1444	-$0.72	$4.22 million	$0.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	12.08	12.08
GALT Galectin Therapeutics	N/A	0.10	0.10
MGNX MacroGenics	N/A	2.96	2.96
XBIT XBiotech	N/A	33.15	33.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
GALT Galectin Therapeutics	11.68%
MGNX MacroGenics	96.89%
XBIT XBiotech	55.70%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.00%
GALT Galectin Therapeutics	52.60%
MGNX MacroGenics	13.60%
XBIT XBiotech	30.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	288	69.99 million	54.60 million	Optionable
GALT Galectin Therapeutics	9	65.86 million	31.22 million	Optionable
MGNX MacroGenics	293	63.70 million	55.04 million	Optionable
XBIT XBiotech	87	30.49 million	21.10 million	Optionable

XBIT, BCYC, GALT, and MGNX Headlines

Recent News About These Companies

XBiotech (NASDAQ:XBIT) Share Price Breaks Below 50-Day Moving Average - Time to Sell?

October 3 at 3:21 AM | americanbankingnews.com

XBiotech (NASDAQ:XBIT) Stock Price Crosses Below Fifty Day Moving Average - Here's What Happened

September 25, 2026 | americanbankingnews.com

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

June 15, 2026 | globenewswire.com

XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar

May 14, 2026 | tipranks.com

XBiotech: Q4 Earnings Snapshot

March 13, 2026 | chron.com

XBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?

October 28, 2025 | msn.com

XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders

August 28, 2025 | finance.yahoo.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

March 2, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

March 1, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 28, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 27, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 26, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 25, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 24, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 23, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 22, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 21, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 20, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 18, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 17, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT, BCYC, GALT, and MGNX Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$3.38 -0.18 (-5.06%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.38 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Galectin Therapeutics NASDAQ:GALT

$3.90 +0.14 (+3.72%)

As of 10/2/2026 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

MacroGenics NASDAQ:MGNX

$3.58 -0.02 (-0.56%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.58 0.00 (-0.14%)

As of 10/2/2026 07:30 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

XBiotech NASDAQ:XBIT

$2.19 -0.01 (-0.45%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.19 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XBIT, BCYC, GALT, and MGNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XBIT, BCYC, GALT, and MGNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XBIT, BCYC, GALT, and MGNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT, BCYC, GALT, and MGNX Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

Galectin Therapeutics NASDAQ:GALT

MacroGenics NASDAQ:MGNX

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XBIT, BCYC, GALT, and MGNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XBIT, BCYC, GALT, and MGNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XBIT, BCYC, GALT, and MGNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT, BCYC, GALT, and MGNX Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

Galectin Therapeutics NASDAQ:GALT

MacroGenics NASDAQ:MGNX

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools